Pharmas will need patient strategies to reap rewards
This article was originally published in Scrip
Unsustainable healthcare costs and the emergence of disruptive innovations is forcing life science companies to embrace a fundamental overhaul of business models to make them more patient-centric and better able to drive behavioural changes in consumers. This is the main conclusion from The third place: health care everywhere, Ernst & Young's latest annual report on the global life sciences industry.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.